Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 16, Number 11—November 2010
Research

Lymphotropism of Merkel Cell Polyomavirus Infection, Nova Scotia, Canada

On This Page
Design and Methods
Results
Discussion
Cite This Article
Figures
Figure
Tables
Table 1
Table 2
Table 3
Table 4
Table 5
Downloads
Article
RIS [TXT - 2 KB]
Article Metrics
Metric Details
43
citations of this article
EID Journal Metrics on Scopus
Author affiliations: Baylor College of Medicine, Houston, Texas, USA (S. Toracchio, V. Sroller, J.A. Reed, C.A. Kozinez, J.S. Butel); Dalhousie University, Halifax, Nova Scotia, Canada (A. Foyle); Queen Elizabeth II Health Science Center, Halifax (A. Foyle); and Public Health Agency of Canada, Ottawa, Ontario, Canada (J. Wu); 1Current affiliation: Institute of Hematology and Blood Transfusion, Prague, Czech Republic

Cite This Article

Abstract

To test the hypothesis that Merkel cell polyomavirus (MCPyV) can infect cells of the lymphoid system, we analyzed 353 specimens, including 152 non-Hodgkin lymphomas, 44 Hodgkin lymphomas, 110 benign lymph nodes, 27 lymph nodes with metastasis, and 20 extranodal tissue samples. MCPyV DNA was detected by quantitative PCR in 13 (6.6%) of 196 lymphomas, including 5 (20.8%) of 24 chronic lymphocytic leukemia specimens, and in 11 (10%) of 110 benign lymph nodes, including 8 (13.1%) of 61 samples of reactive hyperplasia and 3 (10.3%) of 29 normal lymph nodes. Other samples were MCPyV negative. Sequence analysis of 9 virus-positive samples confirmed the identity of MCPyV; 3 viral strains were represented. Immunohistochemical testing showed that 1 T-cell lymphoma expressed MCPyV T-antigen. These findings suggest that the lymphoid system plays a role in MCPyV infection and may be a site for MCPyV persistence.

Merkel cell polyomavirus (MCPyV) was first described in 2008 (1) as a new human virus associated with Merkel cell carcinoma (MCC), an uncommon but aggressive form of skin cancer. Subsequent studies have reported the presence of MCPyV in 24%–100% of MCCs from patients from the United States, Germany, France, the Netherlands, and Australia (1–11). Findings of the clonal integration of MCPyV in tumor cell genomes, tumor-associated mutations in the large T-antigen (T-ag) gene, and large T-ag expression in tumors suggest that MCPyV is not only associated with MCC, but that it may be the causative agent (1,12,13). However, the natural reservoir of MCPyV in infected hosts remains to be identified. MCPyV DNA has been detected at low copy number in some non-MCC skin tumors, in normal tissues of skin and the gastrointestinal tract, and in a few nasopharyngeal aspirates and blood samples, including inflammatory monocytes (1,5,6,11,14–16).

Lymphocytes can disseminate viruses throughout a host and may provide sites of viral persistence. Human polyomaviruses are known to establish persistent infections in healthy persons, to undergo periodic reactivation and replication, and to cause disease in susceptible hosts. Some polyomaviruses are lymphotropic; BK virus, simian virus 40, and JC virus DNA sequences have been detected in human lymphoid tissues, blood cells, and lymphomas (17–20). Recently, Shuda et al. (13) reported the presence of MCPyV in a low percentage (2.2%) of hematolymphoid malignancies. In this study, we investigated the presence of MCPyV in benign lymph nodes and malignant lymphomas in patients from Canada.

Design and Methods

Patients and Samples

This study was approved by the Capital Health Research Ethics Board, Halifax, Nova Scotia, Canada, and by the Baylor College of Medicine Institutional Review Board, Houston. A total of 353 frozen specimens from various body sites were analyzed. Tissues from 196 malignant lymphomas, including 152 non-Hodgkin lymphoma (NHL) and 44 Hodgkin lymphoma (HL) samples, were retrieved from the Department of Anatomical Pathology, Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada.

All cases were diagnosed during 1994 through 2001 and classified according to World Health Organization criteria by using morphologic and immunohistochemical evaluation (21). The NHL samples were classified as B-cell lymphoma (n = 133), NK/T-cell lymphoma (n = 18), or were unclassified (n = 1). The HL samples were classified as classical HL (n = 41) or nodular lymphocyte predominant HL (n = 3). Also included in our study were 157 nonlymphoma frozen tissue specimens, including 110 benign lymph node biopsy specimens from healthy patients or patients with inflammatory disease, 27 lymph nodes from patients with metastatic carcinoma or melanoma, 7 biopsy specimens of inflammatory tissues, and 13 other neoplastic (non-MCC) tissue samples.

Lymphoma specimens were obtained from 96 women and 98 men; patients’ ages ranged from 15 to 88 years (mean 54.5 years). Of the 110 benign lymph nodes, 53 were from women and 57 from men, ranging in age from 17 to 85 years (mean 46 years). Lymph nodes with metastatic tumors were obtained from 16 women and 10 men, ranging in age from 22 to 86 years (mean 60.6 years). Of the 7 inflammatory tissue samples, 3 were from women and 4 were from men 19–84 years of age (mean 52 years). Finally, the non-MCC tumors were obtained from 8 men and 5 women, ranging in age from 22 to 72 years (mean 50.5 years). Data were not available for 3 patients, 2 with lymphoma and 1 with metastatic cancer. The cancers of all lymphoma patients were staged according to the Ann Arbor system (22).

Formalin-fixed, paraffin-embedded biopsy specimens of skin cancers (4 MCCs and 4 melanomas), obtained from the archives of the Department of Pathology, Baylor College of Medicine, Houston, Texas, USA, served as controls for PCR. Specimens were collected during 1998–2008.

Immunohistochemical Analysis

The expression of MCPyV T-ag was detected by immunohistochemical analysis by using a BenchMark XT IHC (Ventana Medical Systems, Inc., Tucson, AZ, USA) system. Tissue sections on microslides were deparaffinized with xylene, hydrated in serially diluted alcohol, and endogenous peroxidase activity was quenched. The sections were then treated with slightly basic Tris-based buffer for 30 min for antigen retrieval. Sections next were incubated with CM2B4, a monoclonal antibody against MCPyV large T-ag (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at a dilution of 1:250, followed by a standard polymer detection kit (diaminobenzidine) that served as the chromogen. The slides were counterstained with hematoxylin, dehydrated, and mounted for examination. A sample from a patient with MCC served as a positive control.

DNA Extraction

DNA was extracted from frozen tissues by lysis buffer/proteinase K treatment and phenol-chloroform extraction as previously described (20), omitting the deparaffinization step. For the paraffin-embedded specimens, sections were deparaffinized, and DNA was extracted by using our previously described protocol (20). During sample processing, stringent precautions were taken to avoid cross-contamination between samples. The microtome was cleaned carefully, and the blade was replaced for sectioning of each tissue. Other safety measures included working within a biosafety hood located in a dedicated room free from plasmids and viruses and using a dedicated set of pipettors and barrier filter tips. In addition, a negative extraction control that lacked tissue was processed in parallel.

Real-Time Quantitative PCR

Samples were first screened for the single-copy human RNase P gene by real-time quantitative PCR (qPCR), as described (20,23). Briefly, 5 μL of each DNA sample (undiluted and 1:10 diluted) was used in 50-μL qPCRs. This strategy detected potential PCR inhibitors in the DNA preparations, determined the human cell equivalents in each DNA sample, and normalized MCPyV viral loads to human cell numbers.

MCPyV was detected by qPCR with primers and TaqMan probe (Applied Biosystems, Foster City, CA, USA) designed to detect sequences from the unique coding region of the small tumor antigen (t-ag) gene of MCPyV. The sequences of the oligonucleotides were as follows: LT3-fwd primer 5′-AGTGTTTTTGCTATCAGTGCTTTATTCT-3′, corresponding to nt 632–659 of MCPyV350 (GenBank accession no. EU375803); LT3-rev primer 5′-CCACCAGTCAAAACTTTCCCA-3′, corresponding to nt 702–682; and fluorogenic probe 5′-FAM-TGGTTTGGATTTCCTC-MGB-3′, corresponding to nt 661–676. The pCR.MCV350 plasmid described by Feng et al. (1) was used as a positive control. Amplifications were performed with the ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) by using the following cycling parameters: 2 min at 50°C, 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and of 1 min at 60°C. All PCRs were performed in duplicate. Reactions were considered positive if >10 viral genome copies/reaction were detected.

Conventional PCR

Conventional PCR was performed on a subset of DNA samples to validate the presence of MCPyV. The primer set used was the following: MC_F2 (5′-CTCATCCTCTGGATCCAGTAGC-3′) and MC_R2 (5′-CAGAAGAGATCCTCCCAGGTG-3′) specific for a conserved region between nt positions 1142 and 1267 of the large T-ag gene of MCPyV (GenBank accession no. EU375803) and gave a 126-bp fragment. The pCR.MCV350 positive control plasmid was added to the control PCR outside the clean room after tubes containing test DNAs and negative controls (without DNA template) were closed. PCRs were performed in a GeneAmp PCR System 2700 thermal cycler (Applied Biosystems). Thermal cycling parameters were as follows: 94°C for 2 min, followed by 45 cycles at 94°C for 15 s, 60°C for 15 s, and 72°C for 15 s, with a final extension step at 72°C for 7 min. Amplified fragments were visualized by electrophoresis on a 3% agarose gel and stained with ethidium bromide. All PCR products were then purified by using the DNA Clean & Concentrator-5 system (Zymo Research, Orange, CA, USA) and sequenced by Lone Star Labs, Inc. (Houston, TX, USA).

Statistical Analysis

The z score of difference for proportions was used to test for a difference between selected groups and an outcome. Fisher exact test was used to test the distribution of clinical stage of disease and 5-year survival category between MCPyV-status groups; a p value <0.05 was considered significant.

Results

DNA Recoveries

DNA was extracted from the specimens and screened for suitability for qPCR analysis by amplification of the cellular RNase P gene. Serial dilutions were tested to determine whether PCR inhibitors were present in the DNA samples and to select noninhibitory dilutions for MCPyV analysis. Total DNA yields ranged from 41 × 104 to 403 × 106 cell equivalents (median 51 × 106) for the lymphoma samples, from 64 × 103 to 216 × 106 cell equivalents (median 29 × 106) for the benign lymph node samples, from 13 × 105 to 117 × 106 cell equivalents (median 21 × 106) for the lymph node samples with metastatic cancer, from 30 × 105 to 78 × 106 cell equivalents (median 39 × 106) for the other inflammatory tissues, and from 16 × 105 to 126 × 106 cell equivalents (median 20 × 106) for the other neoplastic tissues.

MCPyV Detection in MCC

We tested 4 MCC and 4 melanoma samples (fixed and paraffin-embedded) for the presence of MCPyV by qPCR. MCPyV sequences were detected in 2 of 4 MCC samples; none were detected in the 4 melanoma samples (Table 1). MCCs contained an average of 0.29 (range 0.02–0.56) MCPyV genome copies per cell. MCPyV in 1 sample was confirmed by conventional PCR and sequence analysis. The sequence of the amplified fragment showed 98% similarity with the MCC350 reference sequence (GenBank accession no. EU375803) and 100% homology with MCC349 (GenBank accession no. FJ173813).

MCPyV Detection in Malignant Lymphomas, Lymphoid Tissues, and Other Inflammatory or Neoplastic Tissues

A total of 196 frozen malignant lymphoma samples were tested for MCPyV sequences. The classification of those samples is summarized in Table 2. Viral DNA was detected in 13 (6.6%) of the lymphomas (Tables 1, 2). As determined by qPCR, the viral copy numbers were relatively low. An average of 4.6 copies/104 cells (range 0.16–27 copies/104 cells, median 0.94 copies/104 cells) was detected in the MCPyV-positive lymphomas. Among the lymphomas, the overall frequency of MCPyV between NHL and HL cases was similar (6.6% and 6.8%; p = 1.0) (Table 2).

MCPyV was identified most frequently in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (20.8%), a tumor type known to occur in MCC patients (Table 2). Patients with CLL/SLL had a high prevalence of MCPyV compared to all other B-cell lymphomas (20.8% vs. 2.8%; p = 0.01). The virus loads in CLL/SLL were similar to those found in patients with other types of lymphoma. Characteristics of MCPyV-positive and MCPyV-negative CLL/SLL patients are shown in Table 3. None of the 24 CLL/SLL patients had MCC.

A total of 110 frozen benign lymph node samples, 27 lymph nodes with metastatic tumors, and 20 other inflammatory or neoplastic tissues were tested in parallel (Table 4). Eleven of 110 (10%) benign lymph nodes were MCPyV positive (Tables 1, 4). Viral loads in MCPyV-positive lymph nodes averaged 2.3 copies/104 cells (range 0.44–6.0 copies/104 cells, median 2.1 copies/104 cells). Of the 11 benign lymphoid specimens positive for MCPyV DNA, 8 were among 61 (13.1%) reactive hyperplasia samples and 3 were from 29 (10.3%) normal lymph nodes. All other samples tested were negative for MCPyV (Table 4).

Sequence analysis confirmed the qPCR results. Conventional PCR with MCPyV-specific primers was performed on 9 viral DNA-positive samples (4 lymphoma, 5 reactive hyperplasia). DNA amplification products of the expected size (126 bp) from the large T-ag gene were obtained, and sequence analysis confirmed the identity of MCPyV. Three of 4 MCPyV-positive lymphoma samples shared 100% sequence homology with strain MCC344 (GenBank accession no. FJ173807), whereas sequences of the remaining sample were identical to those of MCC349 (GenBank accession no. FJ173813). Among the 5 MCPyV-positive reactive hyperplasia samples, 4 had 100% homology to strain MCC344 and 1 to strain MCC339 (GenBank accession no. EU375804).

Expression of MCPyV T-antigen

Figure

Thumbnail of Merkel cell polyomavirus (MCPyV) large T-antigen (T-ag) expression in human tissues. A) Merkel cell carcinoma stained with CM2B4 antibody as a positive control; MCPyV T-ag was detected. B) Expression of MCPyV T-ag in small lymphocytes in an MCPyV DNA–positive angioimmunoblastic T-cell lymphoma, stained with CM2B4. C) MCPyV DNA–positive reactive lymphoid hyperplasia sample reacted with CM2B4; no T-ag was detected. D) MCPyV DNA-negative chronic lymphocytic leukemia/small lymphocytic l

Figure. Merkel cell polyomavirus (MCPyV) large T-antigen (T-ag) expression in human tissues. A) Merkel cell carcinoma stained with CM2B4 antibody as a positive control; MCPyV T-ag was detected. B) Expression of MCPyV...

A series of 17 lymphoid specimens (7 of which were positive for MCPyV DNA by PCR), consisting of 11 lymphomas and 6 reactive hyperplasia samples, were tested for expression of MCPyV T-ag. Immunohistochemical staining with the CM2B4 monoclonal antibody was carried out without knowledge of the PCR results. One sample, classified as an angioimmunoblastic T-cell lymphoma, expressed detectable T-ag in scattered lymphocytes (Figure). This sample was positive for MCPyV DNA by PCR. The remaining samples tested were negative for T-ag expression by immunohistochemical test.

Clinical Follow-Up

Five-year clinical follow-up information was available for 114 of 196 patients who had malignant lymphoma. Of those patients not included in follow-up analysis, 14 had died from other causes, 47 had received a diagnosis of lymphoma within the past 5 years, and 21 were lost to follow-up. Among the 114 patients with a 5-year follow-up, 49 had died of the disease and 65 were alive (24 with lymphoma and 41 without). Analyses showed no difference in the distributions among survival categories relative to MCPyV status (Table 5). Of the MCPyV-positive patients for whom follow-up data were available, 3 (42.9%) of 7 were alive and in remission compared with 38 (35.5%) of 107 MCPyV-negative patients. There were 3 (42.9%) deaths among the MCPyV-positive group and 46 (43.0%) deaths among the MCPyV-negative group (p = 0.88).

Discussion

This study describes the presence of MCPyV DNA in benign lymph nodes and malignant lymphomas in specimens from patients living in Canada. MCPyV was detected in 6.6% of lymphomas and in 10% of nonneoplastic lymph node samples. These results, together with those of Shuda et al. (13) and Mertz et al. (14), support the hypothesis that lymphocytes and monocytes may serve as a tissue reservoir for MCPyV infection. Because serologic assays have indicated that MCPyV primary infections frequently occur in children (24–26), we favor the interpretation that the MCPyV genomes detected in the adult lymphoid tissues reflect the presence of persistently infected cells. Only 1 specimen among MCPyV DNA–positive samples tested expressed T-ag, which suggests that most infected lymphoid cells are not producing detectable levels of viral protein. However, because MCPyV DNA copy numbers in the samples were low, a few antigen-expressing cells in the tissues may have escaped detection in the immunohistochemical assays.

The data from this study do not suggest that MCPyV caused the lymphoid tumors that were virus positive. However, more comprehensive studies are necessary to exclude the possibility that MCPyV may have lymphomagenic potential under certain conditions. An observation of interest was the presence of MCPyV in 5 (20.8%) of 24 CLL/SLL cases. CLL is a type of leukemia that is now regarded as being identical to SLL (27). The most recent World Health Organization classification scheme for hematopoietic malignancies considers CLL and SLL to be different manifestations of the same disease and combines these entities into 1 disease category (CLL/SLL) (21). Some studies have found that CLL co-exists with MCC, making the association rare but well recognized (28–34). CLL and MCC are age-related with an increased risk in those >60 years of age. Koljonen et al. (35) recently showed that MCPyV DNA is frequently present in MCCs that occur in CLL patients. The basis for the association between CLL and MCPyV is unclear. The link may be coincidental or may reflect some influence of the MCPyV-infection process.

The present study provides evidence of the presence of MCPyV in samples of reactive lymphoid hyperplasia. (Reactive lymphoid hyperplasia refers to a benign, reversible enlargement of the lymph node as a consequence of proliferation of some or all of its cellular components.) This is a normal response of the lymph nodes to an antigenic stimulus, such as infection or inflammation. Viruses, e.g., Epstein-Barr virus, induce reactivity of lymphoid cells in lymphoid tissues from healthy persons (36). In our study, 8 (13.1%) of 61 reactive hyperplasia specimens were shown to harbor MCPyV DNA at low copy number. Whether MCPyV infection prompted those cases of reactive hyperplasia is unknown.

In conclusion, our findings of the presence of MCPyV in malignant lymphomas, reactive hyperplasia, and normal lymph nodes support the hypothesis that MCPyV is lymphotropic. Our findings also suggest that the lymphoid system plays a role in MCPyV infection and may be a site for MCPyV persistence.

Dr Toracchio is an assistant professor in the Department of Medicine, Section of Gastroenterology, at Baylor College of Medicine. Her primary research interests focus on human polyomaviruses, Helicobacter pylori, and human cancer.

Top

Acknowledgments

We thank Patrick Moore for providing the pCR.MCV350 plasmid and Pam Travers for technical assistance with immunohistochemical techniques.

This work was supported by training grant T32 AI007456 (S.T.) and research grant CA104818 (J.S.B.) from the National Institutes of Health and by funding from Health Canada (A.F.).

Top

References

  1. Feng  H, Shuda  M, Chang  Y, Moore  PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319:1096–100 .DOIPubMedGoogle Scholar
  2. Kassem  A, Schöpflin  A, Diaz  C, Weyers  W, Stickeler  E, Werner  M, Frequent detection of Merkel cell polyomavirus in human Merkel cell carcinomas and identification of a unique deletion in the VP1 gene. Cancer Res. 2008;68:5009–13 .DOIPubMedGoogle Scholar
  3. Foulongne  V, Kluger  N, Dereure  O, Brieu  N, Guillot  B, Segondy  M. Merkel cell polyomavirus and Merkel cell carcinoma, France. Emerg Infect Dis. 2008;14:1491–3 .DOIPubMedGoogle Scholar
  4. Paulson  KG, Lemos  BD, Feng  B, Jaimes  N, Peñas  PF, Bi  X, Array-CGH reveals recurrent genomic changes in Merkel cell carcinoma including amplification of L-Myc. J Invest Dermatol. 2009;129:1547–55 .DOIPubMedGoogle Scholar
  5. Becker  JC, Houben  R, Ugurel  S, Trefzer  U, Pföhler  C, Schrama  D. MC polyomavirus is frequently present in Merkel cell carcinoma of European patients. J Invest Dermatol. 2009;129:248–50 .DOIPubMedGoogle Scholar
  6. Garneski  KM, Warcola  AH, Feng  Q, Kiviat  NB, Leonard  JH, Nghiem  P. Merkel cell polyomavirus is more frequently present in North American than Australian Merkel cell carcinoma tumors. J Invest Dermatol. 2009;129:246–8 .DOIPubMedGoogle Scholar
  7. Ridd  K, Yu  S, Bastian  BC. The presence of polyomavirus in non-melanoma skin cancer in organ transplant recipients is rare. J Invest Dermatol. 2009;129:250–2 .DOIPubMedGoogle Scholar
  8. Duncavage  EJ, Zehnbauer  BA, Pfeifer  JD. Prevalence of Merkel cell polyomavirus in Merkel cell carcinoma. Mod Pathol. 2009;22:516–21 .DOIPubMedGoogle Scholar
  9. Sastre-Garau  X, Peter  M, Avril  MF, Laude  H, Couturier  J, Rozenberg  F, Merkel cell carcinoma of the skin: pathological and molecular evidence for a causative role of MCV in oncogenesis. J Pathol. 2009;218:48–56 .DOIPubMedGoogle Scholar
  10. Wetzels  CT, Hoefnagel  JG, Bakkers  JM, Dijkman  HB, Blokx  WA, Melchers  WJ. Ultrastructural proof of polyomavirus in Merkel cell carcinoma tumour cells and its absence in small cell carcinoma of the lung. PLoS ONE. 2009;4:e4958 .DOIPubMedGoogle Scholar
  11. Helmbold  P, Lahtz  C, Enk  A, Herrmann-Trost  P, Marsch  WC, Kutzner  H, Frequent occurrence of RASSF1A promoter hypermethylation and Merkel cell polyomavirus in Merkel cell carcinoma. Mol Carcinog. 2009;48:903–9 .DOIPubMedGoogle Scholar
  12. Shuda  M, Feng  H, Kwun  HJ, Rosen  ST, Gjoerup  O, Moore  PS, T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci U S A. 2008;105:16272–7 .DOIPubMedGoogle Scholar
  13. Shuda  M, Arora  R, Kwun  HJ, Feng  H, Sarid  R, Fernández-Figueras  M, Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors. Int J Cancer. 2009;125:1243–9 .DOIPubMedGoogle Scholar
  14. Mertz  KD, Junt  T, Schmid  M, Pfaltz  M, Kempf  W. Inflammatory monocytes are a reservoir for Merkel cell polyomavirus. J Invest Dermatol. 2010;130:1146–51 .DOIPubMedGoogle Scholar
  15. Goh  S, Lindau  C, Tiveljung-Lindell  A, Allander  T. Merkel cell polyomavirus in respiratory tract secretions. Emerg Infect Dis. 2009;15:489–91 .DOIPubMedGoogle Scholar
  16. Loyo  M, Guerrero-Preston  R, Brait  M, Hoque  MO, Chuang  A, Kim  MS, Quantitative detection of Merkel cell virus in human tissues and possible mode of transmission. Int J Cancer. 2010;126:2991–6.PubMedGoogle Scholar
  17. Patel  NC, Vilchez  RA, Killen  DE, Zanwar  P, Sroller  V, Eldin  KW, Detection of polyomavirus SV40 in tonsils from immunocompetent children. J Clin Virol. 2008;43:66–72 .DOIPubMedGoogle Scholar
  18. Butel  JS. Simian virus 40, human infections, and cancer: emerging concepts and causality considerations. In: Khalili K, Jeang KT, editors. Viral oncology: basic science and clinical applications. Hoboken (NJ): Wiley-Blackwell; 2010. p. 165–89.
  19. Doerries  K. Human polyomavirus JC and BK persistent infection. In: Ahsan N, editor. Polyomaviruses and human diseases. Georgetown (TX): Landes Bioscience; 2006. p. 102–16.
  20. Toracchio  S, Kozinetz  CA, Killen  DE, Sheehan  AM, Banez  EI, Ittmann  MM, Variable frequency of polyomavirus SV40 and herpesvirus EBV in lymphomas from two different urban population groups in Houston, TX. J Clin Virol. 2009;46:154–60 .DOIPubMedGoogle Scholar
  21. Jaffe  ES, Harris  NL, Stein  H, Vardiman  JW. World Health Organization classification of tumours, vol. III. Pathology and genetics: tumours of hematopoietic and lymphoid tissues. Lyon (France): IARC Press; 2001.
  22. Carbone  PP, Kaplan  HS, Mushoff  K, Smithers  DW, Tubiana  M. Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res. 1971;31:1860–1.PubMedGoogle Scholar
  23. McNees  AL, White  ZS, Zanwar  P, Vilchez  RA, Butel  JS. Specific and quantitative detection of human polyomaviruses BKV, JCV, and SV40 by real time PCR. J Clin Virol. 2005;34:52–62 .DOIPubMedGoogle Scholar
  24. Kean  JM, Rao  S, Wang  M, Garcea  RL. Seroepidemiology of human polyomaviruses. PLoS Pathog. 2009;5:e1000363 .DOIPubMedGoogle Scholar
  25. Tolstov  YL, Pastrana  DV, Feng  H, Becker  JC, Jenkins  FJ, Moschos  S, Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays. Int J Cancer. 2009;125:1250–6 .DOIPubMedGoogle Scholar
  26. Carter  JJ, Paulson  KG, Wipf  GC, Miranda  D, Madeleine  MM, Johnson  LG, Association of Merkel cell polyomavirus–specific antibodies with Merkel cell carcinoma. J Natl Cancer Inst. 2009;101:1510–22 .DOIPubMedGoogle Scholar
  27. Kurtin  PJ. Indolent lymphomas of mature B lymphocytes. Hematol Oncol Clin North Am. 2009;23:769–90 .DOIPubMedGoogle Scholar
  28. Ziprin  P, Smith  S, Salerno  G, Rosin  RD. Two cases of Merkel cell tumour arising in patients with chronic lymphocytic leukaemia. Br J Dermatol. 2000;142:525–8 .DOIPubMedGoogle Scholar
  29. Tadmor  T, Aviv  A, Polliack  A. Merkel cell carcinoma, chronic lymphocytic leukemia and other lymphoproliferative disorders: an old bond with possible new viral ties. Ann Oncol. 2010. In press .DOIPubMedGoogle Scholar
  30. Kaae  J, Hansen  AV, Biggar  RJ, Boyd  HA, Moore  PS, Wohlfahrt  J, Merkel cell carcinoma: incidence, mortality, and risk of other cancers. J Natl Cancer Inst. 2010;102:793–801 .DOIPubMedGoogle Scholar
  31. Vlad  R, Woodlock  TJ. Merkel cell carcinoma after chronic lymphocytic leukemia. Case report and literature review. Am J Clin Oncol. 2003;26:531–4 .DOIPubMedGoogle Scholar
  32. Warakaulle  DR, Rytina  E, Burrows  NP. Merkel cell tumour associated with chronic lymphocytic leukaemia. Br J Dermatol. 2001;144:216–7 .DOIPubMedGoogle Scholar
  33. Howard  RA, Dores  GM, Curtis  RE, Anderson  WF, Travis  LB. Merkel cell carcinoma and multiple primary cancers. Cancer Epidemiol Biomarkers Prev. 2006;15:1545–9 .DOIPubMedGoogle Scholar
  34. Rockville Merkel Cell Carcinoma Group. Merkel cell carcinoma: recent progress and current priorities on etiology, pathogenesis, and clinical management. J Clin Oncol. 2009;27:4021–6 .DOIPubMedGoogle Scholar
  35. Koljonen  V, Kukko  H, Pukkala  E, Sankila  R, Böhling  T, Tukiainen  E, Chronic lymphocytic leukaemia patients have a high risk of Merkel-cell polyomavirus DNA-positive Merkel-cell carcinoma. Br J Cancer. 2009;101:1444–7 .DOIPubMedGoogle Scholar
  36. Hudnall  SD, Ge  Y, Wei  L, Yang  NP, Wang  HQ, Chen  T. Distribution and phenotype of Epstein-Barr virus-infected cells in human pharyngeal tonsils. Mod Pathol. 2005;18:519–27 .DOIPubMedGoogle Scholar

Top

Figure
Tables

Top

Cite This Article

DOI: 10.3201/eid1611.100628

Table of Contents – Volume 16, Number 11—November 2010

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Janet S. Butel, Department of Molecular Virology and Microbiology, Baylor College of Medicine, MS: BCM385, 1 Baylor Plaza, Houston, TX 77030-3498, USA

Send To

10000 character(s) remaining.

Top

Page created: March 08, 2011
Page updated: March 08, 2011
Page reviewed: March 08, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external